Serina Therapeutics Stock Price, News & Analysis
Company Description
Serina Therapeutics (NYSE: ser) is a publicly traded biotechnology company in the Pharmaceutical Preparations sector. The company has a market capitalization of $32.1M, ranking #5,881 among all listed U.S. companies by market cap.
ser stock has declined 52.2% over the past year. Shares last traded at $2.27.
On a trailing twelve-month basis, Serina Therapeutics reported revenue of $130K with net income of -$19.2M and diluted earnings per share of $-1.91. The company operates at a net profit margin of -14755.4%.
This page provides a comprehensive overview of ser stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Serina Therapeutics (ser) stock last traded at $2.27, down 10.73% from the previous close. Over the past 12 months, the stock has lost 52.2%. At a market capitalization of $32.1M, ser is classified as a micro-cap stock with approximately 12.3M shares outstanding.
Latest News
Serina Therapeutics has 10 recent news articles, with the latest published 4 days ago. Of the recent coverage, 6 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings, private placement, clinical trial, fda approval. View all ser news →
SEC Filings
Serina Therapeutics has filed 5 recent SEC filings, including 2 Form 8-K, 1 Form 4, 1 Form 10-K/A, 1 Form 10-K. The most recent filing was submitted on March 27, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ser SEC filings →
Insider Radar
Insider selling at Serina Therapeutics over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.
Financial Highlights
Serina Therapeutics generated $130K in revenue over the trailing twelve months, operating income reached -$24.0M (-18478.5% operating margin), and net income was -$19.2M, reflecting a -14755.4% net profit margin. Diluted earnings per share stood at $-1.91. The company generated -$18.0M in operating cash flow. With a current ratio of 1.71, the balance sheet reflects a strong liquidity position.
Upcoming Events
SMC review for Cohort 1
Topline SAD results
Deadline to regain NYSE compliance
Serina Therapeutics has 3 upcoming scheduled events. The next event, "SMC review for Cohort 1", is scheduled for July 1, 2026 (in 93 days). Investors can track these dates to stay informed about potential catalysts that may affect the ser stock price.
Short Interest History
Short interest in Serina Therapeutics (ser) currently stands at 1.0 million shares, up 1079.9% from the previous reporting period, representing 17.9% of the float. Over the past 12 months, short interest has increased by 3210.7%. This moderate level of short interest indicates notable bearish positioning.
Days to Cover History
Days to cover for Serina Therapeutics (ser) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed. The days to cover has decreased 58.2% over the past year, suggesting improved liquidity for short covering. The ratio has shown significant volatility over the period, ranging from 1.0 to 10.4 days.
ser Company Profile & Sector Positioning
Serina Therapeutics (ser) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NYSE.
Investors comparing ser often look at related companies in the same sector, including Vtv Therapeutics (VTVT), Polypid Ltd. (PYPD), JUPITER NEUROSCIENCES, INC. (JUNS), Relmada Therapeutics Inc (RLMD), and MAIA Biotechnology Inc. (MAIA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ser's relative position within its industry.